A breakthrough experimental drug has shown promising results in shrinking advanced prostate cancer tumours, offering new hope ...

Nuvalent's NVL-655 and Zidesamtinib show strong potential as first-line therapies for NSCLC. Click here to find out why I ...

The drug, known as NXP800, works by targeting the heat shock factor 1 (HSF1) pathway, a cellular protective mechanism that is ...

During the 66th American Society of Hematology Annual Meeting and Exposition, investigators revealed early-phase 1 data evaluating various BTK degraders that leverage different strategies to overcome ...

(OTCQB: BIXT) (the "Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced its ...

Research suggests a new drug slowed the growth of prostate cancer cells, including those with a resistance to the hormone ...

A breakthrough in prostate cancer treatment has seen a drug shrink tumours in advanced disease ...

Tongue cancer (TC) cells can enter a chemo-resistant state by activating pathways related to autophagy and cholesterol synthesis, report researchers. Using a large-scale library of TC organoids they ...

Oral cancer is an increasingly prevalent disease worldwide, with over 300,000 new cases diagnosed each year. Among oral cancers, tongue cancer (TC) is ...

Mural nominated two new development candidates, MURA-8518 a novel binding protein-resistant IL-18 with half-life extension, ...

Invikafusp alfa has gained FDA fast track designation for treating TMB-H metastatic colorectal cancer. Invikafusp alfa ...